Main Menu
Main Menu

Viridian Cannabis Deal Tracker

Home / Viridian Cannabis Deal Tracker

The Viridian Cannabis Deal Tracker monitors capital raise, mergers & acquisition, joint venture, and licensing activity for both public and private companies in the legal cannabis industry across 12 key sectors, including Agriculture Technology, Biotech/Pharma, Consulting Services, Consumption Devices, Cultivation & Retail, Hemp, Investments/M&A (Holding Companies), Infused Products & Extracts, Miscellaneous Ancillary, Physical Security, Real Estate, and Software/Media.

Leveraging more than 3 years of data that’s been collected, segmented, and analyzed, the Cannabis Deal Tracker supports smart decision-making by providing sector-specific actionable intelligence and trend analysis in regard to issuers, investors, acquirers, valuations, deal structures, and deal terms.

Viridian Cannabis Deal Tracker – Latest Release

Week ended February 17, 2017

**See below for past releases of the Viridian Cannabis Deal Tracker.

To receive the weekly Viridian Cannabis Deal Tracker, please enter your information in the fields below:

 

Viridian Cannabis Deal Tracker – Past Releases

Week ended February 10, 2017

Week ended February 3, 2017

Week ended January 27, 2017

Week ended January 20, 2017

Week ended January 13, 2017

Week ended January 6, 2017

Week ended December 30, 2016; Year-End Recap

Week ended December 23, 2016

Week ended December 16, 2016

Week ended December 9, 2016

Week ended December 2, 2016

Week ended November 25, 2016

Week ended November 18, 2016

Week ended November 11, 2016

Week ended November 4, 2016

Week ended October 28, 2016

Week ended October 21, 2016

Week ended October 14, 2016

Week ended October 7, 2016

Week ended September 30, 2016

Week ended September 23, 2016

 

 

Disclaimers

The information contained herein is for informational purposes and should not be construed as Viridian recommending investment in cannabis companies or as a solicitation to buy or sell any security or engage in a particular investment strategy. Investment in cannabis companies entails substantial risk. Before acting on any information, you should consider whether it is suitable for your particular circumstances and consult all available material, and, if necessary, seek professional advice.

Viridian Capital Advisors and its affiliates, as well as their respective partners, directors, shareholders, and employees, may have a position in the securities mentioned herein and may make purchases and/or sales from time to time. Viridian Capital Advisors, may act, or may have acted in the past, as a financial advisor, fiscal agent, or underwriter for certain of the companies mentioned herein and may receive, or may have received, a remuneration for their services from those companies.